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Abstract
Purpose  The eVect of gastrectomy on pharmacoki-
netics after S-1 administration was investigated.
Patients and methods  A dose of 40 mg/m2 of S-1 was
administered orally twice daily for 7 days (80 mg/m2/
day) preoperatively in ten patients with resectable gas-
tric cancer, and the same dose of S-1 was administered
for 28 consecutive days after gastrectomy. Plasma con-
centrations of tegafur, gimeracil, and oteracil potas-
sium, all the components of S-1, and 5-FU were
measured on pre- and postoperative days. Concentra-
tions of 5-FU in tumor and normal tissues were also
determined.
Results  At day 4 from the initial preoperative admin-
istration of S-1, the AUC of 5-FU was 1,055 § 304 ng h/
ml. At day 18, day 28, and day 42 after gastrectomy, it
was 1,012 § 331, 1,070 § 403, and 946 § 226 ng h/ml,
respectively. No signiWcant diVerences for plasma 5-FU
were observed between pre- and postoperative days. In
the resected tumor tissues, concentrations of 5-FU were
242 § 83 ng/g around 4.5 h and 91.7 § 37.0 ng/g around
20 h after the Wnal administration, respectively.
Conclusion Gastrectomy does not aVect on pharma-
cokinetics of 5-FU derived from S-1 regardless of par-
tial or total gastrectomy, indicating that S-1 can be a
useful drug in postoperative adjuvant chemotherapy
for gastric cancer.
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Introduction
S-1 (TS-1®) is an oral anticancer drug containing tegafur
(FT), a prodrug of Xuorouracil (5-FU) combined with
two modulators, 5-chloro-2,4-dihydroxypyridine (gimera-
cil, CDHP) and oteracil potassium (Oxo), in a molar
ratio of 1:0.4:1 [10]. CDHP competitively inhibits dihy-
dropyrimidine dehydrogenase (DPD), a key enzyme of
5-FU degradation, in a reversible manner, to maintain
high 5-FU concentrations in plasma and tumors over a
long period of time. Oxo is distributed in the gastrointes-
tinal tract at high concentrations after oral administration
and inhibits phosphorylation of 5-FU in the gastrointesti-
nal tract to enable a reduction in gastrointestinal toxicity
[3, 6, 10, 17]. The response rates were 53.6% (15/28) in an
early phase II study in patients with advanced gastric
cancer including previously treated patients [12]. The
response rate of two pivotal late phase II studies was
49% (25/51) and 40% (20/50), respectively [5, 9]. This
drug exhibits high eYcacy against advanced gastric can-
cer and can be administered at outpatient clinics. Its use
in postoperative adjuvant chemotherapy is thus antici-
pated as a means of improving patients’ quality of life
(QOL). At present, however, no clinical results have
been obtained concerning its use in postoperative adju-
vant chemotherapy. When the use of S-1 as postoperative
adjuvant chemotherapy is considered, a study of the
eVects of gastrectomy on pharmacokinetics promises to
provide important Wndings to determine the daily dose as
well as the dosing schedule for S-1, because all the com-
ponents of S-1 are absorbed in the small intestine.
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whether gastrectomy aVects the pharmacokinetics of
S-1. We also determined tissue concentrations of FU
following preoperative administration of S-1 as a sec-
ondary objective.
Materials and methods
This study was performed according to the guidelines
of the Declaration of Helsinki as amended in Edin-
burgh, Scotland, October 2000, and the protocol was
approved by the Institutional Review Board of Nihon
University School of Medicine.
Patients
Patients enrolled prospectively in the study were required
to meet the following criteria: (1) histologically proven,
resectable gastric cancer; (2) aged 20–74 years old; (3)
Eastern Cooperative Oncology Group performance sta-
tus (PS) 0–2; (4) adequate organ functions deWned as a
leukocyte count of 4,000–12,000, platelet count ¸ 100,000,
serum transaminase (aspartate aminotransferase and ala-
nine aminotransferase) levels · 100 U, serum bilirubin
level · 1.5 mg/dl, and serum creatinine · upper limit of
the normal range; (5) no prior chemotherapy or radio-
therapy; (6) no other severe medical conditions; and (7)
provision of written informed consent by the patients.
Gastric surgery
All patients who were enrolled into this study under-
went curative resection with partial gastrectomy with
Billroth I reconstruction or total gastrectomy with
Roux-en-Y reconstruction according to preoperative
diagnosis.
Study plan
S-1 was administered for seven consecutive days before
surgery. The dosage was determined according to body
surface area (BSA); the Japanese standard dose was
80 mg/m2/day, with 40 mg/m2/dose. The drug was
administered twice daily, within 30 min after breakfast
and dinner, at a dose of 40 mg (20 mg £ 2 capsules) for
BSA < 1.25 m2, 50 mg (25 mg £ 2 capsules) for 1.25 m2
· BSA < 1.50 m2, and 60 mg (20 mg £ 3 capsules) for
BSA > 1.50 m2. The drugs were administered between
8:00 and 9:00 in the morning and between 5:30 and 7:00
in the evening.
Among patients for whom 5-FU concentration in a
tumor was measured, for those receiving S-1 up to and
including the day of surgery, S-1 was administered at
40 mg/m2 under fasting conditions once before surgery
in the morning of the day of surgery. For patients
receiving S-1 up to the evening before surgery, the Wnal
administration of S-1 was conducted the night before
surgery. Postoperative administration of S-1 was con-
ducted orally for 28 consecutive days beginning on day
15 (from day 15 to day 42) after the day of surgery. The
daily dose and times of administration of S-1 were the
same as those in the preoperative S-1 administration
schedule.
Sample collection
Blood samples were collected on a total of 4 days, once
before surgery, in the morning on day ¡4 from the day
of surgery (on day 4 after starting preoperative admin-
istration of S-1), and 3 days after surgery, in the morn-
ing on days 18, 28, and 42 after the day of surgery (on
days 4, 14, and 28 after starting postoperative adminis-
tration of S-1). Blood samples were collected at six
points on each day, before administration and 1, 2, 4, 6,
and 8 h after the administration of S-1. Peripheral
blood samples were collected into a heparinized tube
at a volume of 8 ml at each sampling time and centri-
fuged at 3,000 rpm for 15 min at 4°C; the plasma was
stored at ¡20°C. During surgery, a tissue sample (mini-
mum 1 g) of the primary tumor and a normal tissue
sample (minimum 1 g) were removed together with a
blood sample (1–2 ml). The samples were cleansed of
fat and other debris, quickly frozen, and stored at
¡70°C.
Drug assay
Analysis of FT, 5-FU, CDHP, and Oxo was conducted
according to the method of Matsushima et al. [8]. In
brief, FT was extracted with dichloromethane from
each sample and analyzed using HPLC equipped with
a UV absorption spectrometer. 5-FU and CDHP were
extracted with ethyl acetate from the residue obtained
after dichloromethane extraction, and pentaXuoroben-
zyl derivatives were prepared. 5-FU and CDHP were
analyzed using a negative ion chemical ionization-gas
chromatograph/mass spectrometer (NICI-GC/MS).
Oxo was extracted separately from the samples using a
solid extraction column, then decarbonated, prepared
in a pentaXuorobenzyl derivative, and assayed using
NICI-GC/MS. For the analysis of CDHP, 5-FU, and
Oxo by GC/MS, a stable isotope for each compound
was used as an internal reference. The lower limit of
quantiWcation (LLOQ) of FT, 5-FU, CDHP, and Oxo
in plasma were 10, 1, 2, and 1 ng/ml, respectively.123
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saline with a POLYTRON homogenizer (KINEMAT-
ICA Inc., NJ, USA). The homogenate was then centri-
fuged at 1,000£g for 15 min at 4°C. The supernatant
was used for determination of 5-FU by the above-
mentioned method.
PK parameters
The plasma concentration–time data after administra-
tion of S-1 were analyzed by the noncompartmental
method using a WinNonlin computer program (version
3.1; Pharsight Co, Apex, NC, USA). The peak plasma
concentration (Cmax) and the time to reach the peak
concentration (Tmax) were recorded directly from
experimental observations. The area under the plasma
concentration–time curve (AUC) from time 0 up to 8 h
after administration, AUC0–8 h, was calculated by the
linear trapezoidal method. No weighting factor was
used, and the slope of the terminal phase of the plasma
proWle, K, was determined by log-linear regression of
at least three data points, which yielded a minimum
mean square error. The absolute value of K was used
to estimate the terminal half-life (t1/2) according to the
formula t1/2 = ln 2/K. Since no terminal log-linear phase
was identiWed in a minority of the patients, the t1/2 val-
ues in these patients could not be calculated.
Statistical analysis
Values were expressed as means § standard devia-
tions. As a primary analysis, the eVect of gastrectomy
was tested by an analysis of variance (ANOVA) using
the PK parameters after natural-log transformation.
ANOVA was employed with gastrectomy as a Wxed
eVect and patients as random eVect. Intra-patient var-
iability was considered in the analysis with the covari-
ance structure of compound symmetry. All the data
of patients including unbalanced data were used for
the analysis. As a secondary analysis, a Student’s
paired t test was employed to test the change in PK
parameters of FT, 5-FU, CDHP, and Oxo on days 18,
28, and 42 after the day of surgery comparing with the
data on day 4 (day ¡4 from the day of surgery) after
preoperative S-1 administration. The data were strati-
Wed into two subgroups of patients with partial and
total gastrectomy, and then the data of subgroups
were exploratory analyzed with the same procedure.
SAS for Windows release 8.02 (SAS Institute Inc.,
USA) and Microsoft Excel 2003 (Microsoft Co., Ltd.,




Ten patients who satisWed the eligibility criteria for this
study were included in the analysis. These patients con-
sisted of nine men and one woman, with the median
age of 66 years (range 59–72 years). All patients under-
went curative resection, with Wve patients undergoing
partial gastrectomy with Billroth I reconstruction
and Wve patients undergoing total gastrectomy with
Roux-en-Y reconstruction, respectively.
S-1 administration
The median body surface area of these ten patients was
1.40 m2 (range 1.24–1.86 m2). The dose of S-1 was
80 mg/body/day (40 mg/body/dose twice per day) for
one patient, 100 mg/body/day (50 mg/body/dose twice
per day) for Wve patients, and 120 mg/body/day (60 mg/
body/dose twice per day) for four patients. Preoperative
S-1 administration for 7 days was conducted in all ten
patients as planned. Postoperative S-1 administration
was discontinued in one patient due to development of
stomatitis and diarrhea on day 16 after surgery. A blood
sample could not be collected from one patient due to
anorexia on day 28 after surgery. Both of these patients
had undergone partial gastrectomy.
Pharmacokinetics of FT, 5-FU, CDHP, and Oxo after 
S-1 administration
The mean plasma concentration of FT, 5-FU, CDHP,
and Oxo on day 4 after the start of preoperative S-1
administration (day ¡4 from the day of surgery) (Pre)
and on postoperative days 18 (Post 1), 28 (Post 2), and
42 (Post 3) are shown in Fig. 1. Individual plasma con-
centration–time proWles of 5-FU on the four periods
are shown in Fig. 2.
The PK parameters for FT, 5-FU, CDHP, and Oxo
at each period after administration of S-1 are shown in
Table 1. The AUC0–8 h and Cmax values for FT after
surgery were signiWcantly higher than that before sur-
gery, and the increment tended to be larger on days 28
and 42 after surgery. The eVect of gastrectomy on Cmax
of Oxo was not signiWcant, but that tended to decrease
on day 18 after surgery. The t1/2 values of Oxo after sur-
gery were signiWcantly prolonged compared to that
before surgery. No signiWcant eVect of gastrectomy was
found for 5-FU or CDHP on any of the measurement
days after surgery. Also, no signiWcant change for Tmax
values were observed.123
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The PK parameters for FT, 5-FU, CDHP, and Oxo at
the respective points in time after surgery in Wve
patients undergoing partial gastrectomy with Billroth I
reconstruction are shown in Table 2. The PK parame-
ters of Wve patients undergoing total gastrectomy with
Roux-en-Y reconstruction are shown in Table 3.
Although the data sizes were limited in these sub-
groups, no signiWcant eVect of gastrectomy was found
in patients with partial gastrectomy, however, signiW-
cant changes were observed in patients with total gas-
trectomy as similarly to that found in the overall
analysis. The eVect of gastrectomy on PK of S-1 tended
to be apparent in patients with total gastrectomy.
Concentrations of 5-FU in tumor tissues, 
normal tissues, and plasma
For the four patients who received the Wnal administra-
tion of S-1 in the morning of the day of surgery (time
from the Wnal administration of S-1 to collection of tis-
sues: median = 4 h 35 min, range = 4 h 11 min to 4 h
54 min), the 5-FU concentrations in the tumor tissue was
242 § 83 ng/g, the 5-FU concentration in the normal tis-
sue was 119 § 65 ng/g, and the FU concentration in the
blood was 90.1 § 46.8 ng/ml, with a mean ratio of tumor/
normal tissue of 2.70. In the six patients who received the
Wnal administration of S-1 in the night on the day before
surgery (time from the Wnal administration of S-1 to col-
lection of tissue: median = 19 h 45 min, range = 16 h
45 min to 22 h 45 min), the 5-FU concentration in the
tumor tissue was 91.7 § 37.0 ng/g, the 5-FU concentra-
tion in the normal tissue was 37.2 § 24.4 ng/g, and the 5-
FU concentration in the blood was 8.53 § 10.24 ng/ml,
with a mean ratio of tumor/normal tissue of 8.55.
Fig. 1 Changes of plasma FT (a), 5-FU (b), CDHP (c), and Oxo
(d) after the start of preoperative S-1 administration (Pre) and on
days 18 (Post 1), 28 (Post 2), and 42 (Post 3) after surgery
Fig. 2 Individual concentration–time proWles of 5-FU on day 4
after the start of preoperative S-1 administration (Pre) and on
postoperative days 18 (Post 1), 28 (Post 2), and 42 (Post 3) after
surgery123
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The results of this study show no large change in the
pharmacokinetic parameters of 5-FU after administra-
tion of S-1 due to gastrectomy, indicating that S-1 can
be a useful postoperative adjuvant chemotherapy drug
for gastric cancer. To the best of our knowledge, this is
the Wrst report to investigate the eVect of gastrectomy
on the pharmacokinetics of S-1, based on comprehen-
sive pharmacokinetic analyses of all the components of
S-1, repeatedly in the same patients and at several time
points.
Table 1 PK parameters after 
administration of S-1 for all 
cases (n = 10)
Assay point No. of pts Cmax (ng/ml) Tmax (h) AUC0–8 h (ng h/ml) t1/2
b  (h)
FT Pre 10 2,762 § 1,097 1.7 § 0.9 16,117 § 7,590 9.03 § 4.62
Post 1 10 3,247 § 936 1.8 § 1.2 19,487 § 7,753a 8.43 § 4.86
Post 2 10 3,979 § 1,316a 1.8 § 2.2 23,085 § 10,094a 7.66 § 1.81 (9)
Post 3 8 3,784 § 1,657a 1.8 § 1.0 21,854 § 10,764a 7.69 § 2.59
ANOVA P value 0.0016 0.8585 0.0008 0.7979
SigniWcance P < 0.05 NS P < 0.05 NS
5-FU Pre 10 231 § 73 2.6 § 1.5 1,055 § 304 2.47 § 1.01
Post 1 10 218 § 94 2.2 § 1.0 1,012 § 331 2.80 § 1.73
Post 2 10 219 § 63 3.0 § 2.1 1,070 § 403 2.36 § 0.48 (9)
Post 3 8 194 § 50 2.8 § 1.0 946 § 226 2.59 § 0.73
ANOVA P value 0.3481 0.5363 0.5776 0.3920
SigniWcance NS NS NS NS
CDHP Pre 10 297 § 120 2.2 § 1.3 1,210 § 390 3.49 § 1.44
Post 1 10 212 § 62 1.9 § 1.2 1,018 § 228 4.05 § 1.95 (9)
Post 2 10 373 § 143 2.4 § 2.2 1,533 § 549 3.12 § 0.39 (9)
Post 3 8 335 § 107 2.3 § 1.2 1,468 § 423 3.21 § 1.22
ANOVA P value 0.9970 0.9112 0.5452 0.8613
SigniWcance NS NS NS NS
Oxo Pre 10 82.3 § 31.7 2.3 § 1.3 376 § 180 2.76 § 0.82
Post 1 10 49.5 § 19.4a 2.7 § 1.7 286 § 102 4.25 § 1.28a (6)
Post 2 10 92.2 § 49.3 3.1 § 1.5 496 § 261 4.31 § 1.07a (7)
Post 3 8 90.3 § 28.6 2.8 § 1.4 488 § 214 4.31 § 1.38 (7)
ANOVA P value 0.4041 0.3410 0.7775 0.0070
SigniWcance NS NS NS P < 0.05
a Paired t test, P < 0.05 versus 
Pre
b If missing data exist, the 
number of patients was shown 
in parenthesis
Table 2 PK parameters after 
administration of S-1 for par-
tial gastrectomy cases (n = 5)
Assay point No. of pts Cmax (ng/ml) Tmax (h) AUC0–8 h (ng h/ml) t1/2
a  (h)
FT Pre 5 3,511 § 870 1.8 § 1.3 21,067 § 6,623 9.55 § 5.32
Post 1 5 3,679 § 980 2.0 § 1.2 23,609 § 8,077 11.01 § 5.76
Post 2 5 4,602 § 1,370 2.6 § 3.0 28,264 § 10,135 8.44 § 1.74 (4)
Post 3 3 4,129 § 1,829 2.3 § 1.5 23,973 § 12,397 7.90 § 3.93
ANOVA P value 0.1368 0.4411 0.0521 0.7766
SigniWcance NS NS NS NS
5-FU Pre 5 239 § 27 2.8 § 1.6 1,137 § 197 2.45 § 0.73
Post 1 5 199 § 53 2.8 § 1.1 1,008 § 194 3.38 § 2.32
Post 2 5 223 § 81 3.8 § 2.7 1,156 § 508 2.55 § 0.68 (4)
Post 3 3 203 § 73 3.3 § 1.2 940 § 186 2.74 § 1.21
ANOVA P value 0.1999 0.2212 0.4048 0.1006
SigniWcance NS NS NS NS
CDHP Pre 5 318 § 122 2.0 § 1.2 1,332 § 468 3.34 § 0.89
Post 1 5 229 § 62 2.4 § 1.5 1,134 § 230 4.44 § 2.46
Post 2 5 411 § 187 2.8 § 2.9 1,694 § 673 2.94 § 0.20 (4)
Post 3 3 372 § 160 2.7 § 1.2 1,399 § 368 2.64 § 0.50
ANOVA P value 0.9864 0.4257 0.7741 0.9910
SigniWcance NS NS NS NS
Oxo Pre 5 92.0 § 40.1 2.2 § 1.1 449 § 216 2.76 § 0.72
Post 1 5 48.9 § 12.1 2.4 § 1.5 289 § 34 5.25 (2)
Post 2 5 83.5 § 28.4 3.6 § 1.7 478 § 150 3.90 § 1.26 (3)
Post 3 3 80.2 § 12.9 3.3 § 1.2 465 § 87 3.17 § 0.95 (3)
ANOVA P value 0.3839 0.2923 0.8354 0.1429
SigniWcance NS NS NS NS
a If missing data exist, the 
number of patients was shown 
in parenthesis123
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used instead of uracil in UFT, to enhance eYcacy by
more potent DPD inhibition and containing Oxo to
reduce gastrointestinal toxicity. Sobrero et al. [11] clas-
siWed S-1 as a DPD inhibitory Xuoropyrimidine (DIF).
Yamada et al. [16] reported, based on a comparison of
plasma pharmacokinetics of S-1 and that of 5-FU pro-
tracted venous infusion (PVI) in the Japanese patient
cohort, that the concentration of F--alanine, a catabo-
lite of 5-FU, was signiWcantly lower and plasma uracil
concentrations were signiWcantly higher in the S-1
administration group than in the 5-FU PVI group, thus
clearly demonstrating the eVect of DPD inhibition in
metastatic gastric cancer patients.
Conducting a study of the eVect of gastrectomy on
pharmacokinetics of oral drug is informative guide to
determine how adjuvant chemotherapy should be
administered over a long period after gastrectomy. In
addition, it has been reported that malabsorption of
nutrients due to rapid intestinal transit and bacterial
overgrowth may occur in gastrectomy patients [1, 15].
Maehara et al. [7] studied the eVects of gastric cancer
surgery on the plasma pharmacokinetics of UFT,
which has been widely used in Japan as adjuvant che-
motherapy in patients with gastric cancer. Their results
showed that the plasma pharmacokinetics of 5-FU
after postoperative UFT administration were not inXu-
enced by surgery in patients undergoing total gastrec-
tomy, while 5-FU concentration decreased in the early
postoperative period in patients undergoing partial
gastrectomy. The authors thus conclude that as dose
increases the timing of administration should be given
with careful consideration.
The only available results concerning S-1 were from
a study of pharmacokinetics after a single dose of S-1 in
a clinical phase I study in patients with advanced unre-
sectable and recurrent cancer, in which a comparison
was made between three patients with recurrent gastric
cancer (with no stomach) and nine patients (with stom-
ach) [2]. The study reported that gastrectomy had
almost no eVect on the concentration of 5-FU, and that
the plasma concentration of Oxo was slightly higher in
patients with recurrent gastric cancer. Limitations of
the study included (1) the investigation was not con-
ducted in the same patients, and (2) since the patients
were recurrent cases, a considerable amount of time
had elapsed since gastrectomy, but the numbers of
days after surgery were not included in the study. Most
recently, Tsuruoka et al. also reported on the eVect of
gastrectomy on pharmacokinetics of S-1. They con-
cluded that the AUC0–8 h values of 5-FU and CDHP
after S-1 administration were similar to before surgery
and that gastrectomy had almost no eVect on the phar-
macokinetics of S-1, however, not all components of S-
1 were investigated and only data from around 14 days
after surgery were provided in that study [14]. Clearly,
more detailed studies are necessary. With respect to
the timing of measurement after surgery, especially, a
Table 3 PK parameters after 
administration of S-1 for total 
gastrectomy cases (n = 5)
Assay point No. of pts Cmax (ng/ml) Tmax (h) AUC0–8 h (ng h/ml) t1/2
b  (h)
FT Pre 5 2,014 § 744 1.6 § 0.5 11,168 § 4,952 8.52 § 4.38
Post 1 5 2,814 § 737a 1.6 § 1.3 15,365 § 5,249 5.84 § 1.78
Post 2 5 3,356 § 1,023a 1.0 § 0.0 17,907 § 7,712a 7.04 § 1.79
Post 3 5 3,576 §  1,729a 1.4 § 0.5 20,583 § 10,978a 7.57 § 1.99
ANOVA P value 0.0090 0.2770 0.0101 0.5449
SigniWcance P < 0.05 NS P < 0.05 NS
5-FU Pre 5 222 § 106 2.4 § 1.5 972 § 391 2.48 § 1.33
Post 1 5 237 § 127 1.6 § 0.5 1,016 § 457 2.23 § 0.71
Post 2 5 215 § 50 2.2 § 1.1 984 § 297 2.20 § 0.21
Post 3 5 189 § 40 2.4 § 0.9 949 § 268 2.50 § 0.41
ANOVA P value 0.9011 0.7533 0.7157 0.9608
SigniWcance NS NS NS NS
CDHP Pre 5 275 § 127 2.4 § 1.5 1,088 § 292 3.64 § 1.96
Post 1 5 194 § 63 1.4 § 0.5 903 § 175 3.57 § 1.25 (4)
Post 2 5 335 § 89 2.0 § 1.2 1,372 § 399 3.26 § 0.46
Post 3 5 313 § 75 2.0 § 1.2 1,510 § 489 3.55 § 1.45
ANOVA P value 0.9809 0.4701 0.5690 0.8637
SigniWcance NS NS NS NS
Oxo Pre 5 72.5 § 20.3 2.4 § 1.5 304 § 116 2.75 § 0.99
Post 1 5 50.0 § 26.5 3.0 § 2.0 283 § 149 3.75 § 1.12 (4)
Post 2 5 100.9 § 66.8 2.6 § 1.3 514 § 360 4.62 § 0.98a (4)
Post 3 5 96.3 § 35.0 2.4 § 1.5 502 § 275 5.16 § 0.98a (4)
ANOVA P value 0.8352 0.7863 0.5808 0.0318
SigniWcance NS NS NS P < 0.05
a Paired t test, P < 0.05 versus 
Pre
b If missing data exist, the 
number of patients was shown 
in parenthesis123
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when postoperative adjuvant chemotherapy is generally
started, could provide important data to determine the
optimal initial dose of postoperative S-1 adjuvant che-
motherapy in the future.
The results of our study demonstrated that none of
the pharmacokinetic parameters of 5-FU and CDHP
after administration of S-1 on postoperative days 18,
28, and 42 diVered signiWcantly from those before sur-
gery, indicating that the eVect of gastrectomy on the
safety and eYcacy of S-1 will be small. Similar results
were obtained for the subgroups of patients undergo-
ing partial gastrectomy and total gastrectomy.
On the other hand, signiWcant variations in AUC0–8 h
and Cmax of FT from the preoperative values were
observed on several measurement days after surgery.
Although no signiWcant variations were observed in
patients undergoing partial gastrectomy, patients in both
groups tended to increase in FT level after surgery and
that was apparent in total gastrectomy patients. Since the
twice daily schedule of S-1 treatment limited the sam-
pling over 8 h after drug administration, the half-life time
determined for FT in this study did not correspond to the
true terminal phase. The calculated apparent half-life
ranged from ca. 7 to 9 h, and which is considerably
shorter than that reported by Hirata et al. [2], as ranging
from 13 to 16 h. Therefore, a part of patients who shows
longer half-life time might not reach the steady state on
Pre (day 4 after the start of preoperative S-1 administra-
tion) and on Post 1 (day 4 after the start of postoperative
S-1 administration). The apparent increase in FT level
observed on day 28 and 42 may correlate with the PK
sampling schedule applied in this study.
Taken together with these results, a question may
arise, why the active metabolite 5-FU did not increase
with increase in the level of parent FT? Since the total
body clearance of 5-FU is very large, that cannot
increase in plasma level without inhibitory eVect of
CDHP against DPD. Consequently, the 5-FU exposure
is primarily aVected by concentration of CDHP rather
than the elimination of parent FT. This can be clearly
understood with the correlations between the AUC0–8 h
of 5-FU, FT, and CDHP as shown in Fig. 3. Actually, in
spite of the large diVerence in AUC0–8 h and Cmax of FT
between patients with total gastrectomy and with par-
tial gastrectomy, however 5-FU parameters were simi-
lar in those groups. Therefore, observed diVerence in
FT before and after gastrectomy might not signiWcantly
aVect 5-FU exposure, and probably less clinically
meaningful.
The AUC0–8 h and Cmax of Oxo tended to decrease
on day 18 after surgery, although not statistically sig-
niWcantly, functional disorder due to gastrectomy
might cause defective absorption of Oxo, especially in
the postoperative early stage. Interestingly, signiWcant
diVerences of t1/2 were observed after surgery, and that
was relatively apparent in the total gastrectomy
patients. However for Oxo, its inter-individual variabil-
ity (typically 50% or over as CV) as well as intra-indi-
vidual variability are larger than that of FT, CDHP,
and 5-FU. Therefore, we should pay attention to
understand the result especially for half-life time of
Oxo, because the data was obtained from limited num-
ber of patients.
Kinoshita et al. reported a feasibility study of S-1 in
35 resected gastric cancer patients. In that study, S-1
was administered at 80 mg/m2/day for 4 weeks followed
by 2 weeks of drug suspension as one course starting at
4 weeks after surgery [4]. According to that study, the
planned eight courses of S-1 were administered to 17 of
35 patients (60.7%), and the median percent of actual
administration days with respect to the total number of
planned administration days (28 days £ 8) was 79.0%.
Postoperative administration of S-1 for 1 year thus
seems feasible as adjuvant chemotherapy for gastric
cancer. One problem in that trial was a high incidence
of patient refusal due to adverse reactions, mainly
anorexia, in the Wrst course. The authors mentioned
that a delay in the start of drug administration seems
necessary for adjuvant use to prevent these problems
[4]. Oxo reduces gastrointestinal toxicities including
not only diarrhea but also vomiting [3]. Since Oxo also
Fig. 3 Correlations between 
AUC0–8 h of FT, CDHP, and 
5-FU123
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surgery in our study, this decrease of Oxo may explain,
partly, the causes of anorexia, in addition to the possi-
bilities of surgical stress to patients and limitation of
food intake due to aggressive gastrectomy [4].
In the study of 5-FU concentrations in tumors after
administration of S-1, the concentration of 5-FU in a
tumor around 4.5 h after the Wnal administration of S-1
was 242.13 § 83.02 ng/g. The concentration of 5-FU in
a tumor around 20 h after the Wnal administration was
91.71 § 37.03 ng/g. The mean ratio of 5-FU concentra-
tions in tumors/normal tissue was 8.55, and the mean
ratio of 5-FU concentrations in tissue/plasma was
14.55, indicating favorable retention in tumors over a
long time period. It has been shown that CDHP inhib-
its DPD in the liver to maintain stable 5-FU concentra-
tions and also enhances tumor selectivity due to
inhibition of DPD in tumors [13], Wndings which are
considered to be supported by the results of this study.
In conclusion, this study clariWes that gastrectomy
does not aVect the plasma pharmacokinetics of 5-FU
after postoperative S-1 administration, regardless of
partial or total gastrectomy, and that a stable 5-FU
concentration can be maintained in patients undergo-
ing resection of gastric cancer, although pharmacoki-
netic parameters of Oxo slightly changed after surgery.
Based on these results, suYcient eYcacy of S-1 for
advanced gastric cancer is expected in adjuvant chemo-
therapy. A randomized controlled trial (ACTS-GC
study) has been undertaken to compare surgery alone
versus S-1, administration for 1 year according to the
same schedule as that employed in this study, in
patients with stage II or III gastric cancer who received
curative resection. So far, 1,059 patients have been reg-
istered and a follow-up investigation is currently
underway. If a signiWcant survival beneWt of S-1 is
shown by that trial, this could establish the standard
adjuvant treatment for curatively resected gastric
cancer.
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